# Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

> **NCT00754351** · PHASE2 · COMPLETED · sponsor: **University Hospital of Crete** · enrollment: 48 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00754351
- **Lead sponsor:** University Hospital of Crete
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754351, "Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00754351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*